Literature DB >> 8569742

Disturbances in signal transduction mechanisms in Alzheimer's disease.

C J Fowler1, R F Cowburn, A Garlind, B Winblad, C O'Neill.   

Abstract

Many of the treatments directed towards alleviation of symptoms in Alzheimer's disease assume that target receptor systems are functionally intact. However, there is now considerable evidence that this is not the case. In human post-mortem brain tissue samples, the function of the GTP-binding protein Gs in regulating adenylyl cyclase is severely disabled, whereas that of Gi is intact. This difference in the function of the two G-protein types is also found in G-protein regulation of high- and low-affinity receptor recognition site populations. Measurement of G-protein densities using selective antibodies has indicated that the dysfunction in Gs-stimulation of cAMP production correlates with the ratio of the large to small molecular weight isoforms of the Gs alpha subunit. With respect to intracellular second messenger effects, there is a dramatic decrease in the density of brain receptor recognition sites for Ins(1,4,5)P3 that is not accompanied by a corresponding change in the Ins(1,3,4,5)P4 recognition site density. Protein kinase C function is also altered in Alzheimer's disease, a finding that may be of importance for the control of beta-amyloid production. These studies indicate that signal transduction processes are severely compromised in Alzheimer's disease. Some of these disturbances are also seen in cultured fibroblasts from Alzheimer's disease patients, indicating that they are neither restricted to areas of histopathological change, nor non-specific changes found late in the course of the disease. Cellular models to investigate the relation between amyloid production and deficits in signal transduction are also discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8569742     DOI: 10.1007/bf01076590

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  30 in total

1.  Characterization and regional distribution of adenylyl cyclase activity from human brain.

Authors:  R F Cowburn; A Garlind; C O'Neill; I Alafuzoff; B Winblad; C J Fowler
Journal:  Neurochem Int       Date:  1991       Impact factor: 3.921

2.  Inhibitory effects of beta-amyloid peptides on nicotine-induced Ca2+ influx in PC12h cells in culture.

Authors:  T Takenouchi; E Munekata
Journal:  Neurosci Lett       Date:  1994-05-23       Impact factor: 3.046

Review 3.  The molecular heterogeneity of protein kinase C and its implications for cellular regulation.

Authors:  Y Nishizuka
Journal:  Nature       Date:  1988-08-25       Impact factor: 49.962

4.  Receptor-mediated activation of G proteins is reduced in postmortem brains from Alzheimer's disease patients.

Authors:  H Y Wang; E Friedman
Journal:  Neurosci Lett       Date:  1994-05-23       Impact factor: 3.046

Review 5.  myo-inositol metabolites as cellular signals.

Authors:  C P Downes; C H Macphee
Journal:  Eur J Biochem       Date:  1990-10-05

6.  Altered beta-adrenergic receptor-stimulated cAMP formation in cultured skin fibroblasts from Alzheimer donors.

Authors:  H M Huang; G E Gibson
Journal:  J Biol Chem       Date:  1993-07-15       Impact factor: 5.157

7.  Protein kinase C alteration is an early biochemical marker in Alzheimer's disease.

Authors:  E Masliah; G M Cole; L A Hansen; M Mallory; T Albright; R D Terry; T Saitoh
Journal:  J Neurosci       Date:  1991-09       Impact factor: 6.167

8.  Activation of protein kinase C inhibits cellular production of the amyloid beta-protein.

Authors:  A Y Hung; C Haass; R M Nitsch; W Q Qiu; M Citron; R J Wurtman; J H Growdon; D J Selkoe
Journal:  J Biol Chem       Date:  1993-11-05       Impact factor: 5.157

Review 9.  Role of the beta-amyloid precursor protein in Alzheimer's disease.

Authors:  F Ashall; A M Goate
Journal:  Trends Biochem Sci       Date:  1994-01       Impact factor: 13.807

10.  Preservation of Gi-protein inhibited adenylyl cyclase activity in the brains of patients with Alzheimer's disease.

Authors:  R F Cowburn; C O'Neill; R Ravid; B Winblad; C J Fowler
Journal:  Neurosci Lett       Date:  1992-07-06       Impact factor: 3.046

View more
  7 in total

1.  Hyperactivation of mitogen-activated protein kinase increases phospho-tau immunoreactivity within human neuroblastoma: additive and synergistic influence of alteration of additional kinase activities.

Authors:  F J Ekinci; T B Shea
Journal:  Cell Mol Neurobiol       Date:  1999-04       Impact factor: 5.046

2.  Differential prevention of morphine amnesia by antisense oligodeoxynucleotides directed against various Gi-protein alpha subunits.

Authors:  N Galeotti; C Ghelardini; A Bartolini
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 3.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 4.  A Role for Phosphodiesterase 11A (PDE11A) in the Formation of Social Memories and the Stabilization of Mood.

Authors:  Michy P Kelly
Journal:  Adv Neurobiol       Date:  2017

5.  Efficacy of DL-alpha lipoic acid against systemic inflammation-induced mice: antioxidant defense system.

Authors:  E Philip Jesudason; J Gunasingh Masilamoni; Charles E Jebaraj; Solomon F D Paul; R Jayakumar
Journal:  Mol Cell Biochem       Date:  2008-04-10       Impact factor: 3.396

6.  Molecular profiling reveals diversity of stress signal transduction cascades in highly penetrant Alzheimer's disease human skin fibroblasts.

Authors:  Graziella Mendonsa; Justyna Dobrowolska; Angela Lin; Pooja Vijairania; Y-J I Jong; Nancy L Baenziger
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240

7.  Identification of Dysregulated Genes for Late-Onset Alzheimer's Disease Using Gene Expression Data in Brain.

Authors:  Nibal Arzouni; Will Matloff; Lu Zhao; Kaida Ning; Arthur W Toga
Journal:  J Alzheimers Dis Parkinsonism       Date:  2020-10-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.